T cell receptor-engineered T cells have been heralded as a frontier in targeted cancer therapy, enabling personalized attacks on tumor cells by tailoring the TCR specificity to cancer-associated antigens. However, a persistent limitation has been the suboptimal activity of T cells with low avidity TCRs, which fail to sustain a strong enough signal to effectively eradicate malignant cells. This low avidity often results from the delicate balance needed to avoid off-target toxicity and autoimmunity, constraining the clinical impact of these therapies. The discovery that TIGIT disruption can amplify the otherwise weak TCR signal provides a compelling solution to this stalemate.

TIGIT, or T cell immunoreceptor with Ig and ITIM domains, functions as an immune checkpoint receptor predominantly expressed on T cells and natural killer (NK) cells. It plays a crucial regulatory role by inhibiting immune responses and maintaining self-tolerance. However, in the tumor microenvironment, TIGIT’s inhibitory signaling dampens the antitumor activity of T cells, contributing to immune escape mechanisms leveraged by cancer cells. By genetically disrupting TIGIT in engineered T cells, the researchers effectively removed this inhibitory brake, allowing for a robust amplification of TCR signaling pathways.

Mechanistically, the team demonstrated that TIGIT disruption led to increased phosphorylation cascades downstream of the TCR complex, including key signaling nodes such as ZAP-70, LAT, and ERK. This enhanced intracellular signaling translated into improved functional responses, as TIGIT-deficient T cells exhibited heightened proliferation, cytokine production, and cytotoxicity against tumor cells expressing the target antigen. The increase in signaling strength overcame the intrinsic low avidity of the engineered TCRs, effectively converting them into more potent antitumor effectors without increasing autoreactivity.

Additionally, the study delved deeply into the phenotypic and transcriptional profiles of these TIGIT-deficient T cells. Using single-cell RNA sequencing and flow cytometry analyses, the authors revealed that these cells adopted a more activated and less exhausted state, featuring upregulation of effector molecules such as granzyme B and interferon-gamma. Notably, the modified T cells maintained a memory-like phenotype that favors persistence and long-term tumor surveillance. This phenotype is critical in the context of solid tumors, where continuous antigen exposure often leads to T cell exhaustion and therapeutic failure.

The researchers also explored the impact of TIGIT disruption within the complex tumor microenvironment. Using murine models of solid cancers, they showed that TIGIT-deficient TCR-engineered T cells not only infiltrated tumors more efficiently but also altered the immunosuppressive milieu. Tumors treated with these T cells exhibited lower levels of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), indicating a reshaping of the microenvironment conducive to sustained immune attack. These findings underscore the dual benefit of TIGIT disruption—intrinsic enhancement of TCR signaling and broader modulation of tumor immunity.

Critically, the safety profile of TIGIT disruption was meticulously evaluated. Unlike some checkpoint blockade strategies that unleash widespread immune activation and risk severe autoimmune side effects, the targeted genetic ablation of TIGIT in TCR-engineered T cells appears to retain antigen specificity without promoting off-target toxicity. This selectivity is crucial for clinical translation, as it minimizes the potential for adverse events while maximizing therapeutic benefit.

The study’s authors advocate that this approach could be seamlessly integrated into existing TCR-engineered T cell platforms, offering a scalable path for improved immunotherapy products. Furthermore, they suggest that TIGIT disruption could synergize with other immunomodulatory agents, such as PD-1 blockade or cytokine therapies, to further enhance antitumor responses. Such combination strategies could expand the therapeutic window and efficacy for patients with refractory solid tumors and hematologic malignancies.

From a broader perspective, this research addresses a fundamental challenge in adoptive T cell therapy: balancing T cell receptor affinity and avidity to achieve potent antitumor activity without off-target damage. By focusing on intracellular signaling modulation rather than merely improving TCR binding affinity, the TIGIT disruption strategy provides a novel axis for intervening in T cell functionality. This mechanistic insight could inspire the development of additional checkpoint-modulating approaches to optimize TCR signaling and immune persistence.

The translational potential of this work is underscored by ongoing developments in gene-editing technologies, such as CRISPR/Cas9, which enable precise and efficient TIGIT knockout in therapeutic T cells. Coupled with advances in manufacturing and adoptive transfer protocols, the integration of TIGIT disruption into next-generation T cell products could soon enter clinical testing. This would mark a significant leap forward toward personalized cancer therapies that are both safer and more effective.

Looking ahead, the research community is poised to explore how TIGIT disruption affects the behavior of TCR-engineered T cells in diverse tumor types, including those with notoriously suppressive microenvironments like pancreatic and glioblastoma cancers. Moreover, understanding the long-term consequences of TIGIT loss on T cell metabolism, exhaustion resistance, and memory formation will be critical to fully harnessing this approach. Such investigations will help optimize dosing strategies and identify biomarkers predictive of therapeutic response.

The findings reported by Spiga, Potenza, Magnani et al. represent a pivotal milestone in the field of immune checkpoint biology and adoptive cell therapy. By illuminating the molecular mechanisms through which TIGIT restrains TCR signaling, and demonstrating how its disruption revitalizes low avidity T cells, the researchers have opened new therapeutic avenues. Their work exemplifies the power of combining genetic engineering with immunological insights to overcome longstanding barriers in cancer treatment.

Ultimately, this breakthrough offers renewed hope for patients battling cancers resistant to current immunotherapies. It underscores the dynamic interplay between receptor signaling strength and immune regulation and the potential to tip this balance in favor of durable anticancer immunity. As the oncology field continues to evolve, the refinement of engineered T cell therapies through checkpoint targeting like TIGIT disruption could dramatically reshape clinical outcomes and broaden the reach of life-saving immunotherapies.

Subject of Research:
The study focuses on the disruption of the immune checkpoint receptor TIGIT to enhance the antitumor efficacy of low avidity T cell receptor-engineered T cells by increasing TCR signal strength.

Article Title:
TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength.

Article References:
Spiga, M., Potenza, A., Magnani, Z. et al. TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength. Nat Commun (2026). https://doi.org/10.1038/s41467-025-67263-w

Image Credits:
AI Generated

Acute myeloid leukemia and myelodysplastic syndromes constitute a clinical challenge due to their heterogeneity and the persistence of leukemic stem and progenitor cells that evade conventional chemotherapy and immune surveillance. These stem-like malignant cells reside in tailored protective microenvironments that shield them from cytotoxic agents, leading to refractory disease courses and poor patient prognoses. Targeting surface antigens expressed on these critical subpopulations has thus become a focal point in therapeutic development. CD123, the interleukin-3 receptor alpha chain, is highly overexpressed on leukemic stem and progenitor cells across AML and MDS subtypes while being minimally present on healthy hematopoietic stem cells, rendering it an ideal molecular beacon for selectively driving immune-mediated eradication without undue toxicity to normal tissues.

The unique mechanism of the bispecific AFM28 molecule involves simultaneous engagement of CD123-expressing leukemic cells and innate immune effector cells expressing CD16A, a receptor prominently featured on natural killer (NK) cells. This dual specificity bridges innate immunity with malignant targets, triggering potent antibody-dependent cellular cytotoxicity (ADCC). By leveraging NK cells’ natural cytolytic function, AFM28 orchestrates a precise immunological assault on leukemic populations that are otherwise difficult to overcome. This approach deviates markedly from traditional T cell-engaging therapies, potentially circumventing common adverse effects like cytokine release syndrome while maintaining robust antitumor efficacy.

Comprehensive in vitro and ex vivo analyses demonstrate that AFM28 mediates significant depletion of CD123+ leukemic stem and progenitor cells derived from patient samples. Notably, the therapeutic complex preserves the viability of normal hematopoietic stem cells, underscoring its targeted precision. Functional assays confirm enhanced NK cell activation and degranulation in the presence of AFM28, translating molecular binding into meaningful cell lysis. The specificity and potency of this therapeutic strategy validate innate immune cell engagement as a promising avenue for overcoming the intrinsic resistance mechanisms characteristic of leukemic stem cell niches.

Emerging data from preclinical animal models further substantiate the therapeutic potential of AFM28. In xenograft experiments, administration of AFM28 leads to marked reduction in leukemic burden and significant prolongation of survival compared to controls. These in vivo findings mirror the in vitro efficacy and also highlight the agent’s favorable tolerability profile, an essential consideration in hematological malignancies where patients often endure high treatment-related morbidity. The synergy of bispecific targeting and innate immune activation thus establishes AFM28 as a frontrunner in next-generation immunotherapies aimed at durable disease eradication.

A distinctive advantage of AFM28 lies in its ability to stimulate NK cell-mediated killing independent of antigen presentation pathways that are frequently downregulated in cancer cells. This could circumvent immune evasion mechanisms that limit the success of T cell-centric approaches, especially in tumors with low mutational burden or deficient antigen processing machinery. By harnessing the innate immune arm, AFM28 offers a complementary and possibly synergistic therapeutic modality that may be combined with existing regimens to enhance overall response rates and prevent relapse.

The bispecific design of AFM28 is a testament to advances in molecular engineering that enable precise tailoring of immune effector functions. Constructed to bind with high affinity both CD123 and CD16A, the molecule optimizes the formation of a cytolytic synapse between NK cells and leukemic targets. Structural analyses and affinity maturation efforts underpin its remarkable selectivity and activation potency. This degree of molecular refinement exemplifies the future direction of immunotherapies, moving beyond broad immune modulation toward finely tuned immune engagement.

Clinical translation of AFM28 is underway, with early phase trials evaluating safety, pharmacokinetics, and preliminary efficacy in patients diagnosed with AML and MDS. Initial findings signal promising tolerability and biomarker modulation consistent with target engagement. Patient recruitment efforts focus on those with relapsed or refractory disease, where unmet therapeutic needs are greatest and novel mechanisms of action could provide substantial clinical benefit. Ongoing correlative studies are expected to shed light on optimal dosing strategies and identify predictive biomarkers for response.

The implications of AFM28’s development extend beyond AML and MDS. The platform technology underlying bispecific innate cell engagers harbors versatility that could be adapted to other hematological malignancies and solid tumors with defined antigen targets. The paradigm of directing innate immunity via bispecific molecules broadens the therapeutic arsenal and may overcome limitations experienced by existing immunotherapies. AFM28 thus represents a pioneering step toward more effective, durable, and safer cancer treatments grounded in harnessing innate immune precision.

A challenge remains in fully understanding the dynamics of NK cell recruitment and activation within the tumor microenvironment, which often presents immunosuppressive barriers. Tumor-derived factors can inhibit NK cell function or limit their infiltration, potentially impacting therapeutic outcomes. Strategies to enhance NK cell activity, such as combining AFM28 with cytokines or checkpoint inhibitors targeting innate immune checkpoints, are areas of active investigation. Such combination approaches could amplify the clinical impact of innate cell engagers while preserving manageable safety profiles.

The scientific community also anticipates further elucidation of the molecular interactions at play in AFM28-mediated cytotoxicity. Detailed mechanistic studies examining the engagement kinetics and downstream signaling pathways may reveal opportunities to optimize therapeutic design or identify resistance mechanisms. Furthermore, understanding the interplay between innate and adaptive immunity in response to AFM28 can inform rational combination strategies and the development of next-generation immunotherapeutics.

As data continue to emerge, AFM28 stands as a symbol of the transformative potential when innovative molecular engineering meets the strategic activation of innate immune defenses. This fusion represents a paradigm shift in cancer treatment, moving toward therapies that exploit the body’s natural cellular defenses with unprecedented precision and efficacy. The promise of eradicating leukemic stem cell reservoirs opens a new frontier in the long-sought quest to achieve lasting remission and cure in hematological malignancies.

In essence, the journey from bench to bedside for AFM28 embodies the synthesis of cutting-edge immunology, molecular design, and clinical oncology. It highlights how targeted engagement of the immune system’s innate arm can be harnessed against the most resilient cancer cell populations. As AFM28 progresses through clinical development, it may well herald a new era where bispecific innate cell engagers become foundational tools in the fight against cancer, ultimately improving patient outcomes and transforming lives.

Subject of Research:
Bispecific innate cell engager AFM28 targeting CD123+ leukemic stem and progenitor cells in AML and MDS.

Article Title:
The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS.

Article References:
Schmitt, N., Siegler, JJ., Beck, A. et al. The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. Nat Commun 16, 7793 (2025). https://doi.org/10.1038/s41467-025-63069-y

Image Credits:
AI Generated